How did Pfizer's revenue perform in the first quarter of 2002 compared to the previous year?

Pfizer reported a strong revenue increase of 11% for the first quarter of 2002, reaching $8.4 billion, up from $7.6 billion in the same period of 2001. This growth was attributed to an 11.7% increase in sales volume and a 1.4% price increase, partially offset by a 2.1% negative currency impact.

What was the trend in Pfizer's operating expenses, specifically R&D and merger-related costs?

Research and Development (R&D) expenses increased by 17% to $1.2 billion in the first quarter of 2002, reflecting continued investment in innovation. Conversely, merger-related costs significantly decreased by 59% to $109 million, indicating effective integration of recent business combinations.

How is Pfizer managing its liquidity and capital resources?

Pfizer maintained a strong financial position with $10.1 billion in cash and short-term investments as of March 31, 2002. The company is actively deploying capital through share repurchases, having purchased approximately 25.6 million shares in the first quarter, and increased its cash dividend by 18% to $0.13 per share.

What is Pfizer's outlook for the remainder of 2002?

Pfizer anticipates double-digit revenue growth at current exchange rates for the full year 2002, alongside margin improvements and continued investment in R&D. The company is comfortable with its original target for diluted earnings per share (EPS) in the range of $1.56 to $1.60, despite the negative impact of foreign exchange.

PFE 10-Q Quarterly Report Q1 FY2002 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported strong financial results for the first quarter ended March 31, 2002, demonstrating robust revenue growth and profitability. Total revenues increased by 11% year-over-year to $8.4 billion, driven by significant volume increases and price adjustments across its product lines. The Pharmaceuticals segment, in particular, showed a 12% revenue increase, bolstered by key products like Lipitor, Norvasc, and Zoloft. Net income rose by a healthy 22% to $2.4 billion, with diluted earnings per share (EPS) reaching $0.37. The company also successfully managed its expenses, with R&D spending increasing to support future growth, while merger-related costs continued to decline. The company's financial condition remains strong, with substantial cash and short-term investments available. Pfizer is actively managing its capital resources, including share repurchases and dividend payments, while also investing in its product pipeline. The outlook for 2002 remains positive, with projections for continued double-digit revenue growth and EPS growth, despite potential headwinds from foreign exchange rates. The company continues to navigate legal proceedings and regulatory environments, believing they will not materially impact its financial condition.

Key Highlights

1Revenues surged 11% to $8.4 billion, driven by strong volume growth and price increases, with the Pharmaceuticals segment leading the charge.
2Net income saw a significant increase of 22% to $2.4 billion, translating to diluted EPS of $0.37.
3Research and Development (R&D) expenses increased by 17% to $1.2 billion, underscoring Pfizer's commitment to innovation and future product development.
4Merger-related costs decreased by 59% to $109 million, indicating continued progress in integrating recent acquisitions.
5The company maintained a strong liquidity position with $10.1 billion in cash and short-term investments.
6Pfizer is actively returning capital to shareholders, with cash dividends paid increasing by 18% to $0.13 per share, and significant share repurchases underway.
7The company forecasts double-digit revenue growth and diluted EPS in the range of $1.56 to $1.60 for the full year 2002.

PFIZER INC Quarterly Report for Q1 Ended Mar 31, 2002

Summary

Key Highlights

Frequently Asked Questions